- Home
- FENG vs FEMY Comparison
FENG vs FEMY Comparison
Compare FENG & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENG
- FEMY
- Stock Information
- Founded
- FENG 1998
- FEMY 2004
- Country
- FENG China
- FEMY United States
- Employees
- FENG N/A
- FEMY N/A
- Industry
- FENG Broadcasting
- FEMY Medical/Dental Instruments
- Sector
- FENG Industrials
- FEMY Health Care
- Exchange
- FENG Nasdaq
- FEMY Nasdaq
- Market Cap
- FENG N/A
- FEMY 28.3M
- IPO Year
- FENG 2011
- FEMY 2021
- Fundamental
- Price
- FENG $2.25
- FEMY $0.88
- Analyst Decision
- FENG
- FEMY Strong Buy
- Analyst Count
- FENG 0
- FEMY 3
- Target Price
- FENG N/A
- FEMY $8.67
- AVG Volume (30 Days)
- FENG 10.6K
- FEMY 271.4K
- Earning Date
- FENG 05-14-2025
- FEMY 05-08-2025
- Dividend Yield
- FENG N/A
- FEMY N/A
- EPS Growth
- FENG N/A
- FEMY N/A
- EPS
- FENG N/A
- FEMY N/A
- Revenue
- FENG $97,280,369.00
- FEMY $1,699,232.00
- Revenue This Year
- FENG N/A
- FEMY $441.89
- Revenue Next Year
- FENG N/A
- FEMY $83.88
- P/E Ratio
- FENG N/A
- FEMY N/A
- Revenue Growth
- FENG 1.04
- FEMY 61.97
- 52 Week Low
- FENG $1.28
- FEMY $0.82
- 52 Week High
- FENG $4.15
- FEMY $1.80
- Technical
- Relative Strength Index (RSI)
- FENG 53.58
- FEMY 29.51
- Support Level
- FENG $2.05
- FEMY $0.99
- Resistance Level
- FENG $2.38
- FEMY $1.08
- Average True Range (ATR)
- FENG 0.22
- FEMY 0.05
- MACD
- FENG 0.00
- FEMY -0.01
- Stochastic Oscillator
- FENG 52.08
- FEMY 19.35
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.